In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

CNW/ - Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting a world-first clinical trial evaluating personalized ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or causing death by nearly half compared with Keytruda alone.

The four-year trial of about 70 children with "dismal prognoses" in eight hospitals across Australia will test the safety and ...

The fate of an important breakthrough in cancer immunotherapy treatment remains in the balance following an announcement earlier this week that the Department of Health and Human Services will cancel ...

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively ...